Lunesta Tapering Guide
eszopiclone
Boxed Warning
Complex sleep behaviors (boxed warning class effect for Z-drugs).
Overview
Eszopiclone is the active S-isomer of zopiclone, a non-benzodiazepine Z-drug for insomnia. Longer half-life than zolpidem allows it to address sleep-maintenance insomnia, but also increases next-day impairment.
1mg, 2mg, 3mg tablets
Tablets: 1mg, 2mg, 3mg
Category C
Mechanism of Action
Positive allosteric modulator of the GABA-A receptor — less subunit-selective than zolpidem.
Taper Notes
Slow taper. 1mg increments where possible.
Hyperbolic Tapering Guidance
Same approach as other Z-drugs — hyperbolic taper, behavioral sleep tools, manage rebound insomnia without adding another sedative.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Withdrawal Timeline
1-3 days after stopping
4-7 days
2-6 weeks
Sleep architecture can take 1-3 months to renormalize
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- CNS depressants — additive risk
- Strong CYP3A4 inhibitors — increased exposure
Contraindications
- Prior complex sleep behaviors
- Severe hepatic impairment
Toxicity
Same class effects as zolpidem: complex sleep behaviors, next-day impairment, respiratory depression with CNS depressants. Distinctive metallic/bitter taste.
Pharmacokinetics
ADME Profile
Hepatic via CYP3A4 and CYP2E1.
~52-59%
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Lunesta (eszopiclone) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Buscemi N, Vandermeer B, Friesen C, et al. 2007 — The efficacy and safety of drug treatments for chronic insomnia in adults (Journal of General Internal Medicine)
- Lader M 2014 — Benzodiazepine harm: how can it be reduced? (British Journal of Clinical Pharmacology)
- Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — benzodiazepine receptor agonist algorithm — Evidence-based Z-drug / BZRA deprescribing algorithm
- British National Formulary (BNF) — UK formulary guidance on hypnotic prescribing
- Cochrane Library — Z-drug reviews — Systematic reviews of hypnotic efficacy and safety
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- BenzoBuddies — Z-drug section — Peer-support community covering Z-drug tapering
- Benzodiazepine Information Coalition — Education on benzodiazepine-receptor-agonist dependence
- Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
- Mad in America — sleep medication archive — Journalism on hypnotic prescribing and withdrawal
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.